Clinical Trial Update: Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of cemiplimab and fianlimab before surgery for stage IB-IIIB non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fianlimab (fianlimab)
• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Mayo Clinic | Conditions: Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | Phase 2 | Status: RECRUITING